Citations

Clear

431 citation(s) found for "Schmidt, C".

Infection‐induced proteolysis of PGRP‐LC controls the IMD activation and melanization cascades in Drosophila
Schmidt, Rebecca L., Trejo, Theodore R., Plummer, Timothy B., Platt, Jeffrey L. , Tang, Amy , Tang, Amy H

Mayo Clinic

The FASEB Journal | February 28, 2008 | Volume: 22 | Issue: 3 | Pages: 918-929

10.1096/fj.06-7907com | PMID 18308747 Get It

The Drosophila immune deficiency (IMD) pathway, homologous to the mammalian tumor necrosis factor (TNF‐α) signaling pathway, initiates antimicrobial peptide (AMP) production in response to infection by gram‐negative bacteria. A membrane‐spanning peptidoglycan recognition protein, PGRP‐LC, functions as the receptor for the IMD pathway. This receptor is activated via pattern recognition and binding of monomeric peptidoglycan (DAP‐type PGN) through the PGRP ectodomain. In this article, we show that the receptor PGRP‐LC is down‐regulated in response to Salmonella/Escherichia coli infection but is not affected by Staphylococcus infection in vivo, and an ectodomain‐deleted PGRP‐LC lacking the PGRP domain is an active receptor. We show that the receptor PGRP‐LC regulates and integrates two host defense systems: the AMP production and melanization. A working model is proposed in which pathogen invasion and tissue damage may be monitored through the receptor integrity of PGRP‐LC after host and pathogen are engaged via pattern recognition. The irreversible cleavage or down‐regulation of PGRP‐LC may provide an additional cue for the host to distinguish pathogenic microbes from nonpathogenic ones and to subsequently activate multiple host defense systems in Dro‐sophila, thereby effectively combating bacterial infection and initiating tissue repair.—Schmidt, R. L., Trejo, T. R., Plummer, T. B., Platt, J. L., Tang, A. H. Infection‐induced proteolysis of PGRP‐LC controls the IMD activation and melanization cascades in Drosophila. FASEB J . 22, 918–929 (2008)
Inhibition of RAS-Mediated Transformation and Tumorigenesis by Targeting the Downstream E3 Ubiquitin Ligase Seven in Absentia Homologue
Schmidt, Rebecca L., Park, Cheol Hong, Ahmed, Atique U. , Gundelach, Justin H. , Reed, Nanette R., Shen, Cheng , Tang, Amy , Knudsen, Bruce E. , Tang, Amy H , Ahmed, Atique

Mayo Clinic

Cancer Research | December 18, 2007 | Volume: 67 | Issue: 24 | Pages: 11798-11810

10.1158/0008-5472.can-06-4471 | PMID 18089810 Get It

Abstract Constitutively active RAS small GTPases promote the genesis of human cancers. An important goal in cancer biology is to identify means of countervailing activated RAS signaling to reverse malignant transformation. Oncogenic K-RAS mutations are found in virtually all pancreatic adenocarcinomas, making the RAS pathway an ideal target for therapeutic intervention. How to best contravene hyperactivated RAS signaling has remained elusive in human pancreatic cancers. Guided by the Drosophila studies, we reasoned that a downstream mediator of RAS signals might be a suitable anti-RAS target. The E3 ubiquitin ligase seven in absentia (SINA) is an essential downstream component of the Drosophila RAS signal transduction pathway. Thus, we determined the roles of the conserved human homologues of SINA, SIAHs, in mammalian RAS signaling and RAS-mediated tumorigenesis. We report that similar to its Drosophila counterpart, human SIAH is also required for oncogenic RAS signaling in pancreatic cancer. Inhibiting SIAH-dependent proteolysis blocked RAS-mediated focus formation in fibroblasts and abolished the tumor growth of human pancreatic cancer cells in soft agar as well as in athymic nude mice. Given the high level of conservation of RAS and SIAH function, our study provides useful insights into altered proteolysis in the RAS pathway in tumor initiation, progression, and oncogenesis. By targeting SIAH, we have found a novel means to contravene oncogenic RAS signaling and block RAS-mediated transformation/tumorigenesis. Thus, SIAH may offer a novel therapeutic target to halt tumor growth and ameliorate RAS-mediated pancreatic cancer. [Cancer Res 2007;67(24):11798–810]
Screening for Biotinidase Deficiency in Children with Unexplained Neurologic or Developmental Abnormalities
Sutherland, Steven J., Olsen, Richard D., Michels, Virginia V., Schmidt, Michael A. , O’Brien, John F.

Mayo Clinic

Clinical Pediatrics | November 26, 2007 | Volume: 30 | Issue: 2 | Pages: 81-84

10.1177/000992289103000203 | PMID 1706649 Get It

To test the hypothesis that the frequency of biotinidase deficiency is greater in children with unexplained developmental delay or neurologic abnormalities than in the general population, we studied children seen at a large outpatient clinic over a four-year period who had one or more of these neurologic abnormalities and for whom no specific cause for their abnormalities could be found. The group totaled 274 children (163 boys; 111 girls) whose ages ranged from 2 weeks to 17 years. Characteristics were IQ/DQ, 30 to 70 in the 115 for whom scores were available; 41% had seizures; 15% had sensorineural hearing loss; 54% showed gross motor delay or ataxia; and 27% had decreased muscle tone. One patient with a classical clinical picture of biotinidase deficiency was diagnosed during the study period and was not included in the study. None of the patients with nonclassic findings had a deficiency of biotinidase activity. Our results suggest that biotinidase deficiency does not account for a large proportion of children with unexplained neurologic abnormalities or developmental delay. This does not negate the importance of biotinidase testing in children with clinical patterns specifically suggestive of the deficiency.
Selective Role of an NH2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion–Independent Prostate Cancer Cells
Dehm, Scott M. , Regan, Kevin M., Schmidt, Lucy J., Tindall, Donald J., Dehm, Scott M

Mayo Clinic

Cancer Research | October 17, 2007 | Volume: 67 | Issue: 20 | Pages: 10067-10077

10.1158/0008-5472.can-07-1267 | PMID 17942941 Get It

Abstract Systemic prostate cancer therapy requires androgen ablation, which inhibits the production or action of androgens. Prostate cancer ultimately relapses during androgen ablation, and an androgen depletion-independent (ADI) phenotype emerges. Aberrant androgen receptor (AR) activation underlies therapy resistance at this stage of the disease, and mounting evidence implicates the large and highly disordered AR NH2-terminal domain (NTD) as a key mediator of this activity. In this study, we investigated the role of the NTD transactivation unit 5 (TAU5) domain in mediating AR transcriptional activity in cell-based models of prostate cancer progression. AR replacement and Gal4-based promoter tethering experiments revealed that AR TAU5 had a dichotomous function, inhibiting ligand-dependent AR activity in androgen-dependent prostate cancer cells, while enhancing ligand-independent AR activity in ADI prostate cancer cells. Molecular dissection of TAU5 showed that a WxxLF motif was fully responsible for its ligand-independent activity. Mechanistically, WxxLF did not rely on an interaction with the AR ligand-binding domain to mediate ligand-independent AR activity. Rather, WxxLF functioned as an autonomous transactivation domain. These data show that ligand-dependent and ligand-independent AR activation rely on fundamentally distinct mechanisms, and define WxxLF as the major transactivation motif within the AR TAU5 domain. [Cancer Res 2007;67(20):10067–77]
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
Raza, Azra , Reeves, James A. , Feldman, Eric J. , Dewald, Gordon W., Bennett, John M. , Deeg, H. Joachim , Dreisbach, Luke, Schiffer, Charles A. , Stone, Richard M. , Greenberg, Peter L. , Curtin, Peter , Klimek, Virginia M., Shammo, Jamile M. , Thomas, Deborah A. , Schmidt, M., Wride, Kenton, Zeldis, Jerome B. , List, Alan F. , Knight, Robert

Mayo Clinic

Blood | September 25, 2007 | Volume: 111 | Issue: 1 | Pages: 86-93

10.1182/blood-2007-01-068833 | PMID 17893227 Get It

Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities. We report results of a multicenter, phase 2 trial evaluating lenalidomide therapy for transfusion-dependent patients with low- or int-1–risk MDS without deletion 5q. Eligible patients had 50 000/mm3 or more platelets and required 2 U or more RBCs within the previous 8 weeks; 214 patients received 10 mg oral lenalidomide daily or 10 mg on days 1 to 21 of a 28-day cycle. The most common grade 3/4 adverse events were neutropenia (30%) and thrombocytopenia (25%). Using an intention-to-treat analysis, 56 (26%) patients achieved transfusion independence (TI) after a median of 4.8 weeks of treatment with a median duration of TI of 41.0 weeks. In patients who achieved TI, the median rise in hemoglobin was 32 g/L (3.2 g/dL; range, 10-98 g/L [1.0-9.8 g/dL]) from baseline. A 50% or greater reduction in transfusion requirement occurred in 37 additional patients, yielding a 43% overall rate of hematologic improvement (TI response +‖≥ 50% reduction in transfusion requirement). Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1–risk MDS who lack the deletion 5q karyotypic abnormality. This study is registered at www.clinicaltrials.gov as no. NCT00064974.
Comparative Performance of Two Polyp Detection Systems on CT Colonography
Booya, Fargol, Summers, Ronald M. , Guendel, Lutz, Schmidt, Bernhard , Fidler, Jeff L. , Fletcher, Joel G. , Roy, David P. , McCollough, Cynthia H. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | July 23, 2007 | Volume: 189 | Issue: 2 | Pages: 277-282

10.2214/ajr.07.2289 | PMID 17646451 Get It

Automated Polyp Measurement with CT Colonography: Preliminary Observations in a Phantom Colon Model
Booya, Fargol, Melton, Zachary J. , Guendel, Lutz, Schmidt, Bernhard , Young, Brett M., Fidler, Jeff L. , Harmsen, William S. , Fletcher, Joel G. , Johnson, Kristina T. , McCollough, Cynthia H. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | March 21, 2007 | Volume: 188 | Issue: 4 | Pages: 945-952

10.2214/ajr.06.1169 | PMID 17377028 Get It

Physical Mapping of a Translocation Breakpoint in Neurofibromatosis
Fountain, Jane W., BRUCE, M, Seizinger, Bernd R., Menon, Anil G. , Gusella, James F. , Michels, Virginia V., Schmidt, Michael A. , Dewald, Gordon W., Collins, Francis S. , Wallace, Margaret R.

Mayo Clinic

Science | October 5, 2006 | Volume: 244 | Issue: 4908 | Pages: 1085-1087

10.1126/science.2543076 | PMID 2543076 Get It

The gene for von Recklinghausen neurofibromatosis (NF1), one of the most common autosomal-dominant disorders of humans, was recently mapped to chromosome 17 by linkage analysis. The identification of two NF1 patients with balanced translocations that involved chromosome 17q11.2 suggests that the disease can arise by gross rearrangement of the NF1 locus, and that the NF1 gene might be identified by cloning the region around these translocation breakpoints. To further define the region of these translocations, a series of chromosome 17 Not I-linking clones has been mapped to proximal 17q and studied by pulsed-field gel electrophoresis. One clone, 17L1 (D17S133), clearly identifies the breakpoint in an NF1 patient with a t(1;17) translocation. A 2.3-megabase pulsed-field map of this region was constructed and indicates that the NF1 breakpoint is only 10 to 240 kilobases away from 17L1. This finding prepares the way for the cloning of NF1 .
High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P 3 Lysophospholipid Receptor
Theilmeier, Gregor , Schmidt, Christoph , Herrmann, Jörg, Keul, Petra , Schäfers, Michael , Herrgott, Ilka, Mersmann, Jan , Larmann, Jan , Hermann, Sven , Stypmann, Jörg, Schober, Otmar, Hildebrand, Reinhard, Schulz, Rainer , Heusch, Gerd , Haude, Michael , Lipinski, Karin von Wnuck, Herzog, Christine , Erbel, Raimund, Chun, Jerold , Levkau, Bodo , Schmitz, Martina

Mayo Clinic

Circulation | September 19, 2006 | Volume: 114 | Issue: 13 | Pages: 1403-1409

10.1161/circulationaha.105.607135 | PMID 16982942 Get It

Background— All treatments of acute myocardial infarction are aimed at rapid revascularization of the occluded vessel; however, no clinical strategies are currently available to protect the heart from ischemia/reperfusion injury after restitution of blood flow. We hypothesized that some of the cholesterol transport–independent biological properties of high-density lipoprotein (HDL) implied in atheroprotection may also be beneficial in settings of acute myocardial reperfusion injury. Methods and Results— In an in vivo mouse model of myocardial ischemia/reperfusion, we observed that HDL and its sphingolipid component, sphingosine-1-phosphate (S1P), dramatically attenuated infarction size by ≈20% and 40%, respectively. The underlying mechanism was an inhibition of inflammatory neutrophil recruitment and cardiomyocyte apoptosis in the infarcted area. In vitro, HDL and S1P potently suppressed leukocyte adhesion to activated endothelium under flow and protected rat neonatal cardiomyocytes against apoptosis. In vivo, HDL- and S1P-mediated cardioprotection was dependent on nitric oxide (NO) and the S1P 3 lysophospholipid receptor, because it was abolished by pharmacological NO synthase inhibition and was completely absent in S1P 3 -deficient mice. Conclusions— Our data demonstrate that HDL and its constituent, S1P, acutely protect the heart against ischemia/reperfusion injury in vivo via an S1P 3 -mediated and NO-dependent pathway. A rapid therapeutic elevation of S1P-containing HDL plasma levels may be beneficial in patients at high risk of acute myocardial ischemia.
Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension
Elliott, C. Gregory , Glissmeyer, Eric W. , Havlena, Gregory T., Carlquist, John F., McKinney, Jason T., Rich, Stuart , McGoon, Michael D., Scholand, Mary Beth , Kim, Miryoung, Jensen, Robert L., Schmidt, Jon W., Ward, Kenneth, Havlena, Gregory T.

Mayo Clinic

Circulation | May 22, 2006 | Volume: 113 | Issue: 21 | Pages: 2509-2515

10.1161/circulationaha.105.601930 | PMID 16717148 Get It

Background— Vasoreactivity tests are fundamental in evaluating pulmonary arterial hypertension (PAH). Mutations of the transforming growth factor-β type II receptor gene, BMPR2 , predispose to the development of pulmonary hypertension and may alter the response to vasodilators. Previous investigations have not examined the relationship of BMPR2 mutations to vasoreactivity. Methods and Results— We identified 133 consecutive unrelated patients with either idiopathic or familial PAH. Sixty-six patients were excluded because we lacked either DNA samples (n=18) or complete data from a vasoreactivity test (n=48). The remaining 67 patients were screened for BMPR2 DNA sequence variations, and specific variations were confirmed by gene sequencing. The vasoreactivity of patients with nonsynonymous BMPR2 variations was compared with that of patients without nonsynonymous BMPR2 variations. We found nonsynonymous BMPR2 variations in 27 of 67 patients with idiopathic (n=16 of 52) or familial (n=11 of 15) PAH. Vasoreactivity was identified in 3.7% of 27 patients with nonsynonymous BMPR2 variations and in 35% of 40 patients without nonsynonymous BMPR2 variations ( P =0.003). Five of the 27 nonsynonymous variations occur commonly in healthy individuals. None of the remaining 22 patients with BMPR2 variations demonstrated vasoreactivity, and the analysis remained unchanged when we assumed that nonsynonymous BMPR2 variations were present in all 15 patients with familial PAH. Conclusions— Patients with familial or idiopathic PAH and nonsynonymous BMPR2 variations are unlikely to demonstrate vasoreactivity. Further trials are required to determine whether long-term therapy can be directed by tests for BMPR2 variations.